Dementia Alzheimer Articles & Analysis
16 news found
“With this patent in place, we have enhanced the value of our portfolio, including our lead candidate OLX-07010 which will begin first-in-human clinical trials soon.” According to the Alzheimer’s Association, more than 6.5 million Americans suffer from AD. ...
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for ...
“We are extremely pleased to receive this R44 grant which will allow us to plan for a Phase 1b, doubleblind clinical study of OLX-07010 in patients with Alzheimer’s disease,” said William Erhardt, M.D., President and Head of Development at Oligomerix. ...
Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases. Diseases like Dementia and Alzheimer’s afflict millions of people across the globe, while over 1 billion people worldwide – 1 in 6 – suffer from a ...
Published in EPMA Journal, the study explored sex differences in Altoida’s digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimer’s Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker ...
Published in EPMA Journal, the study explored sex differences in Altoida’s digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimer’s Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker ...
About TRANQUILITY II and III Initiated in December of 2021, TRANQUILITY II and III are pivotal Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with Alzheimer’s disease. The trials expand the evaluation of patients who experience agitation across diverse medical settings and across the range of dementia severity. ...
(NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: ...
Data presented at AAIC demonstrates oral lead product candidate OLX-07010 reduces tau self-association and insoluble tau aggregates Oligomerix to begin clinical testing of OLX-07010 in 2Q22 Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced ...
There is a critical unmet need for novel approaches to treating Alzheimer’s disease and other rare neurodegenerative disorders, and I believe that our pioneering therapy can make a significant impact in the field,” said Dr. ...
Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard ...
This exemplary research demonstrates the power of Cognistat computerized assessment system to detect Mild Cognitive Impairment (MCI), the earliest recognizable phase of Alzheimer dementia.” said Jonathan Mueller, MD, Chief Medical Officer of ...
We are SO EXCITED to support the first Charity Gala for Hope for Dementia that will take place on January 31, 2019 in Montreal, QC! Join us for an unforgettable evening of Live Entertainment, Dignitary Speeches from Local & Community Leaders and Touching Story-Telling to support Hope for Dementia! ...
It could also be caused by smoking or bad air quality (pollution). Ones who suffer from dementia or Alzheimer’s also cannot communicate what they feel, and this makes the diagnosis even ...
ByuHoo